Antenatal Examinations: What to Expect and When

During pregnancy, regular antenatal examinations are important to monitor the health and development of both the mother and the fetus. Here are some key points to keep in mind:

Symphysis-fundal height: This measurement should be taken at every antenatal appointment from 24 weeks of gestation onwards.

Blood pressure and urine dipstick: These should be checked at every antenatal examination, especially in late pregnancy when pre-eclampsia is more common.

Abdominal palpation for fetal presentation: This should only be done at or after 36 weeks of gestation, as it is more accurate and can influence management of delivery. If an abnormal presentation is suspected, an ultrasound scan should be performed.

Ultrasound scan: Routine scanning after 24 weeks of gestation is not recommended.

Fetal movement counting: This is not routinely offered.

Fetal heart rate with hand-held doppler ultrasound: Routine auscultation is not recommended, but may be done to reassure the mother if requested.

By following these guidelines, healthcare providers can ensure that antenatal examinations are conducted safely and effectively.

Management of Prolonged First Stage of Labour: Interventions and Considerations

When a patient experiences a prolonged first stage of labour, it is important to assess the three categories where problems could arise: Powers, Passage, and Passenger. In the case of a primigravida who is achieving less than 0.5 cm per hour over the past 6 hours, and with irregular, non-powerful contractions, the first step is to perform a vaginal examination to assess cervical dilation, fetal position and presentation, and membrane integrity. If the membranes are intact, an amniotomy or artificial rupture of membranes can be performed to accelerate the first stage of labour. Progress is then reassessed by vaginal examination after two hours. If progress remains suboptimal, an oxytocin infusion can be commenced, with analgesia taken into consideration. However, oxytocin infusion should be avoided in women with a previous Caesarean section due to the risk of uterine rupture.

If there is no indication of fetal distress, uncontrolled haemorrhage, or other maternal complications, there is no need for a Caesarean section or instrumental delivery at present. However, if fetal distress or serious maternal complications arise, an emergency Caesarean section would be the preferred mode of delivery. In the absence of these indications, an intervention such as amniotomy should be offered early to increase the chances of a normal vaginal delivery before the patient tires. Therefore, reassessment should be done in one hour to ensure timely intervention.

If a woman with stage IA cervical cancer wants to maintain her fertility, a cone biopsy with negative margins and close follow-up may be considered as the best option. Hysterectomy with or without lymph node clearance would not preserve fertility. Radical trachelectomy, which involves removing the cervix, upper part of the vagina, and surrounding tissues, and checking for cancer spread in the pelvis, is an option for IA2 tumors that also preserves fertility.

Management of Cervical Cancer Based on FIGO Staging

Cervical cancer management is determined by the FIGO staging and the patient’s desire to maintain fertility. The FIGO staging system categorizes cervical cancer into four stages based on the extent of the tumor’s spread. Stage IA and IB tumors are confined to the cervix, with IA tumors only visible under a microscope and less than 7 mm wide. Stage II tumors have spread beyond the cervix but not to the pelvic wall, while stage III tumors have spread to the pelvic wall. Stage IV tumors have spread beyond the pelvis or involve the bladder or rectum.

The management of stage IA tumors involves a hysterectomy with or without lymph node clearance. For patients who want to maintain fertility, a cone biopsy with negative margins can be performed, but close follow-up is necessary. Stage IB tumors are managed with radiotherapy and concurrent chemotherapy for B1 tumors and radical hysterectomy with pelvic lymph node dissection for B2 tumors.

Stage II and III tumors are managed with radiation and concurrent chemotherapy, with consideration for nephrostomy if hydronephrosis is present. Stage IV tumors are treated with radiation and/or chemotherapy, with palliative chemotherapy being the best option for stage IVB. Recurrent disease is managed with either surgical treatment followed by chemoradiation or radiotherapy followed by surgical therapy.

The prognosis of cervical cancer depends on the FIGO staging, with higher survival rates for earlier stages. Complications of treatments include standard surgical risks, increased risk of preterm birth with cone biopsies and radical trachelectomy, and ureteral fistula with radical hysterectomy. Complications of radiotherapy include short-term symptoms such as diarrhea and vaginal bleeding and long-term effects such as ovarian failure and fibrosis of various organs.

To avoid teratogenic effects, both men and women must discontinue the use of methotrexate for at least 6 months before attempting to conceive. Methotrexate inhibits dihydrofolate reductase, which affects DNA synthesis and can harm the rapidly dividing cells of the fetus. Additionally, methotrexate can damage various semen parameters. It is not enough for only the patient to stop taking methotrexate; both partners must cease use. Taking folic acid during pregnancy does not counteract the harmful effects of methotrexate on folate metabolism and does not address the partner’s use of the drug. Waiting for 3 months is insufficient; both partners must wait for 6 months to ensure that methotrexate will not cause teratogenic effects.

Managing Rheumatoid Arthritis During Pregnancy

Rheumatoid arthritis (RA) is a condition that commonly affects women of reproductive age, making issues surrounding conception and pregnancy a concern. While there are no official guidelines for managing RA during pregnancy, expert reviews suggest that patients with early or poorly controlled RA should wait until their disease is more stable before attempting to conceive.

During pregnancy, RA symptoms tend to improve for most patients, but only a small minority experience complete resolution. After delivery, patients often experience a flare-up of symptoms. It’s important to note that certain medications used to treat RA are not safe during pregnancy, such as methotrexate and leflunomide. However, sulfasalazine and hydroxychloroquine are considered safe.

Interestingly, studies have shown that the use of TNF-α blockers during pregnancy does not significantly increase adverse outcomes. However, many patients in these studies stopped taking the medication once they found out they were pregnant. Low-dose corticosteroids may also be used to control symptoms during pregnancy.

NSAIDs can be used until 32 weeks, but should be withdrawn after that due to the risk of early closure of the ductus arteriosus. Patients with RA should also be referred to an obstetric anaesthetist due to the risk of Atlantoaxial subluxation. Overall, managing RA during pregnancy requires careful consideration and consultation with healthcare professionals.

Pregnant women with a BMI of ≥30 kg/m² should be given a high dose of 5mg folic acid to prevent neural tube defects (NTD) in the first trimester of pregnancy. This is in addition to patients with diabetes, sickle cell disease (SCD), thalassaemia trait, coeliac disease, on anti-epileptic medication, personal or family history of NTD, or who have previously given birth to a baby with an NTD. Folic acid should ideally be started before conception to further reduce the risk of NTD. However, a history of asthma, smoking, patient age, and Asian ethnicity are not indications for high-dose folic acid prescribing in pregnancy. Pregnant smokers should not be prescribed high-dose folic acid, although smoking during pregnancy is a risk factor for prematurity, low birth weight, and cleft lip/palate. There is currently no evidence to support high-dose folic acid prescribing for pregnant women with asthma or those at the extremes of maternal age. Additionally, all pregnant women should take vitamin D 10mcg (400 units) daily throughout their pregnancy, as recommended by NICE.

Folic Acid: Importance, Deficiency, and Prevention

Folic acid is a vital nutrient that is converted to tetrahydrofolate (THF) in the body. It is found in green, leafy vegetables and plays a crucial role in the transfer of 1-carbon units to essential substrates involved in the synthesis of DNA and RNA. However, certain factors such as phenytoin, methotrexate, pregnancy, and alcohol excess can cause a deficiency in folic acid. This deficiency can lead to macrocytic, megaloblastic anemia and neural tube defects.

To prevent neural tube defects during pregnancy, it is recommended that all women take 400mcg of folic acid until the 12th week of pregnancy. Women at higher risk of conceiving a child with a neural tube defect should take 5mg of folic acid from before conception until the 12th week of pregnancy. Women are considered higher risk if they or their partner has a neural tube defect, they have had a previous pregnancy affected by a neural tube defect, or they have a family history of a neural tube defect. Additionally, women with certain medical conditions such as coeliac disease, diabetes, or thalassaemia trait, or those taking antiepileptic drugs, or who are obese (BMI of 30 kg/m2 or more) are also considered higher risk.

In summary, folic acid is an essential nutrient that plays a crucial role in DNA and RNA synthesis. Deficiency in folic acid can lead to serious health consequences, including neural tube defects. However, taking folic acid supplements during pregnancy can prevent these defects and ensure a healthy pregnancy.

Diagnosing Gestational Trophoblastic Disease: Differential Diagnosis

Gestational trophoblastic disease is a rare condition that can present with symptoms similar to other pregnancy-related complications. When evaluating a patient with suspected gestational trophoblastic disease, it is important to consider the differential diagnosis and rule out other potential causes.

One common misdiagnosis is occlusion of the coronary vessels, as there is no association between gestational trophoblastic disease and coronary artery disease. Rupture of the fallopian tube may be a possibility if the patient had an ectopic pregnancy, but the history and examination are not suggestive of this. Septic miscarriage is also a possibility, but the symptoms and examination findings in this scenario are more typical of gestational trophoblastic disease.

Twin or triplet pregnancy is unlikely due to the absence of foetal parts and the elevated blood pressure. Instead, gestational trophoblastic disease should be considered when a patient presents with bleeding in early pregnancy, severe hyperemesis, new-onset hypertension prior to 20 weeks’ gestation, and a uterus that is larger than expected. An extremely elevated β-HCG and a classical ultrasound appearance resembling a ‘snow storm’ are also indicative of gestational trophoblastic disease.

It is important to note that gestational trophoblastic disease is strongly associated with thyroid dysfunction and that the lungs are among the first sites of metastatic disease. By considering the differential diagnosis and conducting appropriate testing, healthcare providers can accurately diagnose and treat gestational trophoblastic disease.

During pregnancy, it is recommended to avoid consuming liver due to its high levels of vitamin A, which is a teratogen.

Antenatal Care: Lifestyle Advice for Pregnant Women

During antenatal care, healthcare providers should provide pregnant women with lifestyle advice to ensure a healthy pregnancy. The National Institute for Health and Care Excellence (NICE) has made several recommendations regarding the advice that pregnant women should receive. These recommendations include nutritional supplements, alcohol consumption, smoking, food-acquired infections, work, air travel, prescribed medicines, over-the-counter medicines, complimentary therapies, exercise, and sexual intercourse.

Nutritional supplements such as folic acid and vitamin D are recommended for pregnant women. However, iron supplementation should not be offered routinely, and vitamin A supplementation should be avoided as it may be teratogenic. Pregnant women should also avoid alcohol consumption as it can lead to long-term harm to the baby. Smoking should also be avoided, and women who have stopped smoking may use nicotine replacement therapy (NRT) after discussing the risks and benefits with their healthcare provider.

Pregnant women should also be cautious of food-acquired infections such as listeriosis and salmonella. They should avoid certain foods such as unpasteurized milk, ripened soft cheeses, pate, undercooked meat, raw or partially cooked eggs, and meat, especially poultry. Women should also be informed of their maternity rights and benefits at work, and the Health and Safety Executive should be consulted if there are any concerns about possible occupational hazards during pregnancy.

Air travel during pregnancy should also be approached with caution. Women who are over 37 weeks pregnant with a singleton pregnancy and no additional risk factors should avoid air travel. Women with uncomplicated, multiple pregnancies should avoid air travel once they are over 32 weeks pregnant. Pregnant women should also avoid certain activities such as high-impact sports where there is a risk of abdominal trauma and scuba diving. However, sexual intercourse is not known to be associated with any adverse outcomes during pregnancy.

Overall, pregnant women should be informed of these lifestyle recommendations to ensure a healthy pregnancy and reduce the risk of harm to the baby.

Causes of Second-Trimester Miscarriage: Incomplete Fusion of Paramesonephric Ducts and Other Factors

Second-trimester miscarriage can have various causes, including a septate or bicornuate uterus, cervical incompetence, and antiphospholipid syndrome or systemic lupus erythematosus. One possible reason for a septate or bicornuate uterus is incomplete fusion of the paramesonephric ducts. However, other factors such as low maternal serum progesterone or a failure of migration of gonadotropin-releasing hormone (GnRH)-secreting neurones from the olfactory placode can also contribute to second-trimester miscarriage. It is important to consider all possible causes when investigating recurrent pregnancy loss.

This patient has intrahepatic cholestasis of pregnancy, which is characterized by abnormal liver function tests and severe itching in the third trimester. This condition increases the risk of stillbirth and maternal complications, particularly after 37 weeks of gestation. Therefore, induction of labor is typically recommended at this point, especially for patients with elevated transaminases and bile acids. While increased fetal monitoring is advised, hospitalization is not necessary unless there are signs of immediate concern for the fetus. A vaginal birth is usually appropriate, and a cesarean section is rarely required unless there are indications of non-reassuring fetal status. Although antihistamines can provide symptomatic relief, they are not sufficient on their own due to the risks associated with this condition. Other options for symptom relief include ursodeoxycholic acid, cholestyramine, and topical emollients. There is no indication for immediate delivery, as fetal movements and ultrasound results are normal.

Intrahepatic Cholestasis of Pregnancy: Symptoms and Management

Intrahepatic cholestasis of pregnancy, also known as obstetric cholestasis, is a condition that affects approximately 1% of pregnancies in the UK. It is characterized by intense itching, particularly on the palms, soles, and abdomen, and may also result in clinically detectable jaundice in around 20% of patients. Raised bilirubin levels are seen in over 90% of cases.

The management of intrahepatic cholestasis of pregnancy typically involves induction of labor at 37-38 weeks, although this practice may not be evidence-based. Ursodeoxycholic acid is also widely used, although the evidence base for its effectiveness is not clear. Additionally, vitamin K supplementation may be recommended.

It is important to note that the recurrence rate of intrahepatic cholestasis of pregnancy in subsequent pregnancies is high, ranging from 45-90%. Therefore, close monitoring and management are necessary for women who have experienced this condition in the past.

Options for Management of Miscarriage: Surgical Evacuation, Misoprostol, Expectant Management, and Mifepristone

Miscarriage is a common complication of pregnancy, affecting up to 20% of all pregnancies. When a miscarriage occurs, there are several options for management, including surgical evacuation, misoprostol, expectant management, and mifepristone.

Surgical evacuation of products of conception involves a general anaesthetic, dilation of the cervix, and removal of the products by curettage. Risks associated with this procedure include bleeding, infection, venous thromboembolism, retained products of conception, intrauterine adhesions, uterine perforation, and cervical damage.

Misoprostol is a prostaglandin E1 analogue that promotes uterine contraction, cervical ripening, and dilation. It can be used for medical management of a missed or incomplete miscarriage or for induction of labor. However, if medical management fails, as in the case of the patient in this scenario, misoprostol is not appropriate.

Expectant management is the first-line management of women with a confirmed missed or incomplete miscarriage. However, if expectant management is unacceptable to the patient or in the presence of other factors, such as a previous pregnancy complication, medical or surgical management should be offered.

Mifepristone is a competitive antagonist of progesterone that disrupts and degenerates the decidualized endometrium, causes ripening and dilation of the cervix, and increases the sensitivity of the myometrium to the effect of prostaglandins. When used in combination with misoprostol, it is the recommended regimen for medical termination of pregnancy.

In conclusion, the management of miscarriage depends on several factors, including the patient’s preference, medical history, and clinical presentation. The options for management include surgical evacuation, misoprostol, expectant management, and mifepristone. It is important to discuss the risks and benefits of each option with the patient to make an informed decision.